Phase II study of mifepristone (RU-486) in the treatment of PR [progesterone-receptor]-positive advanced/recurrent endometrial adenocarcinoma and low grade endometrial stromal sarcoma (LGESS)

Trial Profile

Phase II study of mifepristone (RU-486) in the treatment of PR [progesterone-receptor]-positive advanced/recurrent endometrial adenocarcinoma and low grade endometrial stromal sarcoma (LGESS)

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2012

At a glance

  • Drugs Mifepristone (Primary)
  • Indications Endometrial cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Apr 2010 Actual patient number (13) added as reported by ClinicalTrials.gov.
    • 30 Mar 2010 Actual end date (1 May 2008) added as reported by ClinicalTrials.gov.
    • 17 Jan 2008 The expected completion date for this trial is now 1 Sep 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top